21 Sep Clinical Conundrums in ITP, Dr. Mark Crowther (9/18/23) – Webinar Case
Speaker: Mark Crowther, MD MSc FRCPC FRSC
Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research
McMaster University
Learning Objectives:
- Identify common issues in the management of ITP.
- Distinguish between those patients who do, and do not, require therapy.
- Appraise evidence for novel therapies in this area.
Answer and track your answers to these questions before watching the webinar:
Q1 : Which therapy is most likely to result in a safe platelet count 1 year after treatment discontinuation
a. Splenectomy
b. Steroids
c. Rituximab
Q2 : Secondary ITP is seen in association SLE
a. Commonly
b. Rarely
c. Almost never
Q3 : After a failed first course of steroids, most experts would
a. Provide a second course of steroids
b. Use rituximab
c. Use a tPO agonist
There will be a quiz following your video viewing.
Scientific Planning Committee
Dr. Pallavi Ganguli – Resident Physician, Hematology
Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre
Conflict of Interest: None